Literature DB >> 1568744

Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus.

J E McArdle1, K J Lewin, G Randall, W Weinstein.   

Abstract

To assess the anatomic relationships between areas of dysplasia and "early" carcinoma, we evaluated histologically the entire mucosal surfaces of seven esophagectomy specimens resected for high-grade dysplasia or early invasive (intramucosal and submucosal) carcinoma. We developed surface area maps and assessed the various degrees of dysplasia or carcinoma at 10 equidistant points. Our analysis shows an equal likelihood of high-grade dysplasia and/or early invasive carcinoma occurring throughout the length of Barrett's epithelium. Foci of carcinoma appear within fields of Barrett's epithelium and adjacent to areas of dysplasia, supporting a dysplasia-carcinoma sequence. The amount of dysplastic epithelium appears related to the surface area of Barrett's epithelium present. However, we found no association between the extent of dysplasia and the likelihood of finding carcinoma. This study supports the current standard of practice for clinical surveillance of patients with Barrett's esophagus by uniformly distributed endoscopic biopsy of the complete length. In addition, the presence of any degree of dysplasia may be an indication for close clinical follow-up.

Entities:  

Mesh:

Year:  1992        PMID: 1568744     DOI: 10.1016/0046-8177(92)90123-k

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  27 in total

1.  Barrett's esophagus: is dysplasia a reliable marker in surveillance after endoscopic treatment?

Authors:  M A Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-10

2.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

3.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 4.  High grade dysplasia: surveillance, mucosal ablation, or resection?

Authors:  Robert J Korst; Nasser K Altorki
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

5.  Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases.

Authors:  F A Carey; W A Wallace; R J Fergusson; K M Kerr; D Lamb
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

Review 6.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

7.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  M J Edwards; D R Gable; A B Lentsch; J D Richardson
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

8.  Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.

Authors:  Ewa E Hennig; Michal Mikula; Janina Orlowska; Dorota Jarosz; Andrzej Bielasik; Jaroslaw Regula; Jerzy Ostrowski
Journal:  J Mol Med (Berl)       Date:  2007-10-19       Impact factor: 4.599

9.  Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.

Authors:  J L Van Laethem; M Cremer; M O Peny; M Delhaye; J Devière
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

Review 10.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.